董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cameron Reynolds | 男 | President,Chief Executive Officer and Director | 47 | 69.00万美元 | 未持股 | 2018-07-20 |
| Martin Faulkes | 男 | Executive Chairman and Director | 74 | 43.68万美元 | 未持股 | 2018-07-20 |
| Guy Innes | 男 | Director | 62 | 10.45万美元 | 未持股 | 2018-07-20 |
| Alan Colman | 男 | Director | 69 | 11.70万美元 | 未持股 | 2018-07-20 |
| Habib Skaff | 男 | Director | 41 | 8.27万美元 | 未持股 | 2018-07-20 |
| Edward Futcher | 男 | Director | 64 | 8.76万美元 | 未持股 | 2018-07-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cameron Reynolds | 男 | President,Chief Executive Officer and Director | 47 | 69.00万美元 | 未持股 | 2018-07-20 |
| Rodney Rootsaert | 男 | Corporate Secretary | 47 | 26.27万美元 | 未持股 | 2018-07-20 |
| Jason Terrell | 男 | Chief Medical Officer and Head of U.S. Operations | 38 | 23.12万美元 | 未持股 | 2018-07-20 |
| Martin Faulkes | 男 | Executive Chairman and Director | 74 | 43.68万美元 | 未持股 | 2018-07-20 |
| Jacob Micallef | 男 | Chief Scientific Officer | 62 | 41.94万美元 | 未持股 | 2018-07-20 |
| David Vanston | 男 | Chief Financial Officer and Treasurer | 50 | 未披露 | 未持股 | 2018-07-20 |
董事简历
中英对照 | 中文 | 英文- Cameron Reynolds
-
Cameron Reynolds 担任我们总裁，首席执行官和董事。在换股协议之前，他是新加坡Volition的首席执行官和董事，自2010年8月5日起一直担任此职务。自2010年10月27日起，他也担任比利时 Volition的董事；2012年1月18日至2015年7月24日，担任董事总经理；自2011年3月7日起，担任Hypergenomics的董事兼首席执行官；2015年11月13日，被任命为Volition Diagnostics UK Limited的董事兼首席执行官。2004年至2011年，Reynolds先生创办并担任Mining House Limited的管理董事，他在那里负责识别潜在的矿业项目、协调初步评估和保护AIM、TSX和美国场外交易的公司融资。2002年至2003年，Reynolds先生进一步教育，获得工商管理硕士学位。1998年至2001年，Reynolds先生曾担任 Probio, Inc.（一家动物生物技术领域知识产权的商业化公司，包括University of Hawaii的转基因和克隆研究）的商业总监。 Reynolds先生的主要职责是管理University of Hawaii所有法律和合同问题；实施专利战略；管理所有股东问题，包括并购的法律和合同文件；总行管理；预算控制；团队建设和招聘。此外，1996年Reynolds先生曾在Integrated Coffee Technologies担任初级管理职位，这是一家转基因咖啡公司在那里他负责业务计划的制定、办公管理、招聘和企业发展。1994年开始Reynolds先生在Southern China Group任职，在那里担任地区经理，在香港和云南设立业务。2005年至目前，Reynolds先生多次担任董事会董事职务，包括Atlantic Mining PLC； Carbon Mining PLC, Magellan Copper 和 Gold Carbon Mining和MCG都成为Solfotara Mining and Copper Development Corp.的一部分； KAL Energy Inc.（KALG，OTC），Iofina Natural Gas PLC（IOF，AIM）；Canyon Copper Corp.（TSX.V：CNC，OTCBB：CNYC）和Hunter Bay Resources（HBY，TSX-V）。
Cameron Reynolds serves as our President, Chief Executive Officer and Director. Prior to completion of the transactions under the Share Exchange Agreement, he was Chief Executive Officer and Director of Singapore Volition, a position he held since August 5 2010. He is also a Director of Belgian Volition since October 27 2010 serving as Managing Director between January 18 2012 and July 24 2015 a Director and Chief Executive Officer of Hypergenomics since March 7 2011 was appointed Director and Chief Executive Officer of Volition Diagnostics on November 13 2015 and was appointed Director of Volition America on February 3 2017. Since February 2017 Mr. Reynolds has also served as a non-executive director of Ucroo Inc., a developer of a secure web and mobile platform that integrates with existing college systems to provide a thriving digital campus where students are better connected, supported and engaged, and, since July 2018 as a non-executive director of OBJ Limited ASX: OBJ, a developer of magnetic, micro-array drug and ingredient delivery technologies for use in pharmaceutical, cosmetic and skincare, and consumer healthcare industries. From 2004 until 2011 Mr. Reynolds founded and served as Managing Director and Director of Mining House, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on the AIM, the TSX and the U.S. OTC. Mr. Reynolds furthered his education between 2002 and 2003 as he undertook an MBA. From 1998 until 2001 Mr. Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds’ main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all stockholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment. Furthermore, Mr. Reynolds held a junior management position in 1996 at Integrated Coffee Technologies, a genetically modified coffee company where he was responsible for business plan creation, office management, recruitment, and business development. Starting in 1994 Mr. Reynolds was working for Southern China Group, where as regional manager he set up operations in Hong Kong and Yunnan. Between 2005 and 2011 Mr. Reynolds held a number of board directorships including Atlantic Mining PLC; Carbon Mining PLC; Magellan Copper and Gold (Carbon Mining and MCG both became part of Solfotara Mining and Copper Development Corp.); KAL Energy Inc. (OTC: KALG); Iofina Natural Gas PLC (AIM: IOF); Canyon Copper Corp. (TSX-V: CNC, OTCBB: CNYC); and Hunter Bay Resources (TSX-V: HBY). - Cameron Reynolds 担任我们总裁，首席执行官和董事。在换股协议之前，他是新加坡Volition的首席执行官和董事，自2010年8月5日起一直担任此职务。自2010年10月27日起，他也担任比利时 Volition的董事；2012年1月18日至2015年7月24日，担任董事总经理；自2011年3月7日起，担任Hypergenomics的董事兼首席执行官；2015年11月13日，被任命为Volition Diagnostics UK Limited的董事兼首席执行官。2004年至2011年，Reynolds先生创办并担任Mining House Limited的管理董事，他在那里负责识别潜在的矿业项目、协调初步评估和保护AIM、TSX和美国场外交易的公司融资。2002年至2003年，Reynolds先生进一步教育，获得工商管理硕士学位。1998年至2001年，Reynolds先生曾担任 Probio, Inc.（一家动物生物技术领域知识产权的商业化公司，包括University of Hawaii的转基因和克隆研究）的商业总监。 Reynolds先生的主要职责是管理University of Hawaii所有法律和合同问题；实施专利战略；管理所有股东问题，包括并购的法律和合同文件；总行管理；预算控制；团队建设和招聘。此外，1996年Reynolds先生曾在Integrated Coffee Technologies担任初级管理职位，这是一家转基因咖啡公司在那里他负责业务计划的制定、办公管理、招聘和企业发展。1994年开始Reynolds先生在Southern China Group任职，在那里担任地区经理，在香港和云南设立业务。2005年至目前，Reynolds先生多次担任董事会董事职务，包括Atlantic Mining PLC； Carbon Mining PLC, Magellan Copper 和 Gold Carbon Mining和MCG都成为Solfotara Mining and Copper Development Corp.的一部分； KAL Energy Inc.（KALG，OTC），Iofina Natural Gas PLC（IOF，AIM）；Canyon Copper Corp.（TSX.V：CNC，OTCBB：CNYC）和Hunter Bay Resources（HBY，TSX-V）。
- Cameron Reynolds serves as our President, Chief Executive Officer and Director. Prior to completion of the transactions under the Share Exchange Agreement, he was Chief Executive Officer and Director of Singapore Volition, a position he held since August 5 2010. He is also a Director of Belgian Volition since October 27 2010 serving as Managing Director between January 18 2012 and July 24 2015 a Director and Chief Executive Officer of Hypergenomics since March 7 2011 was appointed Director and Chief Executive Officer of Volition Diagnostics on November 13 2015 and was appointed Director of Volition America on February 3 2017. Since February 2017 Mr. Reynolds has also served as a non-executive director of Ucroo Inc., a developer of a secure web and mobile platform that integrates with existing college systems to provide a thriving digital campus where students are better connected, supported and engaged, and, since July 2018 as a non-executive director of OBJ Limited ASX: OBJ, a developer of magnetic, micro-array drug and ingredient delivery technologies for use in pharmaceutical, cosmetic and skincare, and consumer healthcare industries. From 2004 until 2011 Mr. Reynolds founded and served as Managing Director and Director of Mining House, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on the AIM, the TSX and the U.S. OTC. Mr. Reynolds furthered his education between 2002 and 2003 as he undertook an MBA. From 1998 until 2001 Mr. Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds’ main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all stockholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment. Furthermore, Mr. Reynolds held a junior management position in 1996 at Integrated Coffee Technologies, a genetically modified coffee company where he was responsible for business plan creation, office management, recruitment, and business development. Starting in 1994 Mr. Reynolds was working for Southern China Group, where as regional manager he set up operations in Hong Kong and Yunnan. Between 2005 and 2011 Mr. Reynolds held a number of board directorships including Atlantic Mining PLC; Carbon Mining PLC; Magellan Copper and Gold (Carbon Mining and MCG both became part of Solfotara Mining and Copper Development Corp.); KAL Energy Inc. (OTC: KALG); Iofina Natural Gas PLC (AIM: IOF); Canyon Copper Corp. (TSX-V: CNC, OTCBB: CNYC); and Hunter Bay Resources (TSX-V: HBY).
- Martin Faulkes
-
Martin Faulkes担任董事会执行主席。在换股协议之前，2010年8月18日至2015年12月15日Faulkes博士曾担任新加坡Volition的董事；2011年3月22日至2015年12月15日，担任新加坡Volition的董事会执行主席。自2011年8月10日起，Faulkes先生一直担任比利时Volition的董事。1998年至今，Faulkes博士一直专注于慈善活动，如担任Dill Faulkes Educational Trust（一家英国注册的慈善机构）的创办人及捐助人，在那里他是主席。他还任职英国剑桥800周年活动的委员会。在Faulkes博士的慈善活动前，他创立Triad公共有限公司（一家计算机软件开发公司，提供系统和商界顾问），在那里他是1987年至1998年担任董事，并负责公司的财务控制。1985年至1987年，他成为了System Programming Ltd.（向航空公司、公用事业公司、银行和Insurance Company提供计算机编程服务的一家公司）的执行董事，在那里他负责该业务的所有方面的业务。在 System Programming Ltd.之前，1979年至1984年Faulkes博士担任Logica Inc.（一家向所有行业提供定制软件的公司，但主要是银行和通信公司）的总裁兼首席执行官。 Faulkes博士负责业务的各个方面；即销售、财务、招聘、员工管理和项目控制。
Martin Faulkes serves as Executive Chairman of the Board of Directors. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Faulkes served as a Director of Singapore Volition from August 18 2010 to December 15 2015 and as Executive Chairman of the Board of Directors of Singapore Volition from March 22 2011 until December 15 2015. Dr. Faulkes also served as a Director of Belgian Volition between August 10 2011 and March 31 2016. From 1998 until the present day, Dr. Faulkes has focused on charitable activities, as the founder and sole benefactor of The Dill Faulkes Educational Trust, a U.K. registered charity, where he is Chairman. He also sits on the board of the Cambridge 800th Anniversary Campaign in the U.K. Prior to Dr. Faulkes’s charitable activities he founded Triad Plc., a computer software development company that provides systems and consultants to the business community, where he was a Director from 1987 to 1998 and responsible for controlling the company financially. From 1985 to 1987 he became Managing Director of System Programming Ltd., a company that provides computer programming for systems in businesses such as airlines, utility companies, banks, and insurance companies, where he was responsible for all aspects of the business. Prior to System Programming Ltd., Dr. Faulkes served from 1979 to 1984 as founder, President and Chief Executive Officer for Logica Inc., a company providing bespoke software to all industries but mainly banks and communications companies. Dr. Faulkes was responsible for all aspects of the business, including sales, finance, recruitment, staff management and project control. - Martin Faulkes担任董事会执行主席。在换股协议之前，2010年8月18日至2015年12月15日Faulkes博士曾担任新加坡Volition的董事；2011年3月22日至2015年12月15日，担任新加坡Volition的董事会执行主席。自2011年8月10日起，Faulkes先生一直担任比利时Volition的董事。1998年至今，Faulkes博士一直专注于慈善活动，如担任Dill Faulkes Educational Trust（一家英国注册的慈善机构）的创办人及捐助人，在那里他是主席。他还任职英国剑桥800周年活动的委员会。在Faulkes博士的慈善活动前，他创立Triad公共有限公司（一家计算机软件开发公司，提供系统和商界顾问），在那里他是1987年至1998年担任董事，并负责公司的财务控制。1985年至1987年，他成为了System Programming Ltd.（向航空公司、公用事业公司、银行和Insurance Company提供计算机编程服务的一家公司）的执行董事，在那里他负责该业务的所有方面的业务。在 System Programming Ltd.之前，1979年至1984年Faulkes博士担任Logica Inc.（一家向所有行业提供定制软件的公司，但主要是银行和通信公司）的总裁兼首席执行官。 Faulkes博士负责业务的各个方面；即销售、财务、招聘、员工管理和项目控制。
- Martin Faulkes serves as Executive Chairman of the Board of Directors. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Faulkes served as a Director of Singapore Volition from August 18 2010 to December 15 2015 and as Executive Chairman of the Board of Directors of Singapore Volition from March 22 2011 until December 15 2015. Dr. Faulkes also served as a Director of Belgian Volition between August 10 2011 and March 31 2016. From 1998 until the present day, Dr. Faulkes has focused on charitable activities, as the founder and sole benefactor of The Dill Faulkes Educational Trust, a U.K. registered charity, where he is Chairman. He also sits on the board of the Cambridge 800th Anniversary Campaign in the U.K. Prior to Dr. Faulkes’s charitable activities he founded Triad Plc., a computer software development company that provides systems and consultants to the business community, where he was a Director from 1987 to 1998 and responsible for controlling the company financially. From 1985 to 1987 he became Managing Director of System Programming Ltd., a company that provides computer programming for systems in businesses such as airlines, utility companies, banks, and insurance companies, where he was responsible for all aspects of the business. Prior to System Programming Ltd., Dr. Faulkes served from 1979 to 1984 as founder, President and Chief Executive Officer for Logica Inc., a company providing bespoke software to all industries but mainly banks and communications companies. Dr. Faulkes was responsible for all aspects of the business, including sales, finance, recruitment, staff management and project control.
- Guy Innes
-
Guy Innes担任董事。在换股协议之前，Innes先生担任新加坡Volition的董事，2010年8月18日至2015年12月15日一直担任此职务。Innes先生担任公司的非执行董事，如 2007年至2010年的Carbon Mining Plc，2007年至2010年的Magellan Copper & Gold Plc，2000年至2006年的ProBio公司。作为非执行董事，Innes先生负责公司战略发展，财务控制和风险管理制度的执行情况。Innes先生曾在银行和私募股权有漫长的职业生涯，其中包括1997年至2000年在Quartz Capital Partners Limited担任咨询职务，在那里Innes先生担任公司财务总监，负责管理公司财务部门和领导 Quartz所进行的交易包括首次公开发行、私募和并购；1995年至1997年在伦敦和新加坡Baring Private Equity Partners Limited，在那里他曾参与设立、管理和融资亚洲媒体和私募基金；1984年至1995年在伦敦和巴黎的Baring Brothers & Co. Limited任职，他参与并执行国家和国际并购咨询，首次公开发行和资金筹集。
Guy Innes serves as a Director. Prior to completion of the transactions under the Share Exchange Agreement, Mr. Innes served as a Director of Singapore Volition, a position he held from August 18 2010 to December 15 2015. Mr. Innes has served as a non-executive Director on the board of companies such as Carbon Mining PLC. from 2007 to 2010 Magellan Copper & Gold PLC. from 2007 to 2010 and ProBio Inc. from 2000 to 2006. As a non-executive Director, Mr. Innes was responsible for the development of corporate strategy and the implementation of financial controls and risk management systems. Mr. Innes had a long career in banking and private equity, including advisory roles with Quartz Capital Partners Limited from 1997 to 2000 where Mr. Innes served as Head of Corporate Finance and was responsible for managing the corporate finance department and leading the transactions undertaken by Quartz including IPOs, private placements and mergers and acquisitions; Baring Private Equity Partners Limited in London and Singapore from 1995 to 1997 where he was involved in the setting up, recruiting of managers and capital raising for an Asian media and communications private equity fund; and Baring Brothers & Co. Limited in London and Paris from 1984 to 1995 where he was involved in executing and advising on national and international mergers and acquisitions, but also IPOs and capital raising. Mr. Innes is a Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales. - Guy Innes担任董事。在换股协议之前，Innes先生担任新加坡Volition的董事，2010年8月18日至2015年12月15日一直担任此职务。Innes先生担任公司的非执行董事，如 2007年至2010年的Carbon Mining Plc，2007年至2010年的Magellan Copper & Gold Plc，2000年至2006年的ProBio公司。作为非执行董事，Innes先生负责公司战略发展，财务控制和风险管理制度的执行情况。Innes先生曾在银行和私募股权有漫长的职业生涯，其中包括1997年至2000年在Quartz Capital Partners Limited担任咨询职务，在那里Innes先生担任公司财务总监，负责管理公司财务部门和领导 Quartz所进行的交易包括首次公开发行、私募和并购；1995年至1997年在伦敦和新加坡Baring Private Equity Partners Limited，在那里他曾参与设立、管理和融资亚洲媒体和私募基金；1984年至1995年在伦敦和巴黎的Baring Brothers & Co. Limited任职，他参与并执行国家和国际并购咨询，首次公开发行和资金筹集。
- Guy Innes serves as a Director. Prior to completion of the transactions under the Share Exchange Agreement, Mr. Innes served as a Director of Singapore Volition, a position he held from August 18 2010 to December 15 2015. Mr. Innes has served as a non-executive Director on the board of companies such as Carbon Mining PLC. from 2007 to 2010 Magellan Copper & Gold PLC. from 2007 to 2010 and ProBio Inc. from 2000 to 2006. As a non-executive Director, Mr. Innes was responsible for the development of corporate strategy and the implementation of financial controls and risk management systems. Mr. Innes had a long career in banking and private equity, including advisory roles with Quartz Capital Partners Limited from 1997 to 2000 where Mr. Innes served as Head of Corporate Finance and was responsible for managing the corporate finance department and leading the transactions undertaken by Quartz including IPOs, private placements and mergers and acquisitions; Baring Private Equity Partners Limited in London and Singapore from 1995 to 1997 where he was involved in the setting up, recruiting of managers and capital raising for an Asian media and communications private equity fund; and Baring Brothers & Co. Limited in London and Paris from 1984 to 1995 where he was involved in executing and advising on national and international mergers and acquisitions, but also IPOs and capital raising. Mr. Innes is a Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales.
- Alan Colman
-
Alan Colman担任董事。在换股协议之前，2011年4月1日至2015年12月15日Cole曼博士曾担任新加坡 Volition的董事；自2011年4月5日起，担任新加坡 Volition科学顾问委员会主席。1971年，Cole曼博士获得Oxford University学士学位，1975年获得Oxford University硕士学位和Oxford University博士学位。Cole曼博士目前是Harvard University干细胞与再生生物学院的访问学者。2007年至2013年，Cole曼博士曾担任新加坡干细胞协会的执行主任。同时，2008年至2009年Cole曼博士是英国伦敦国王学院再生医学的教授。在加入A * STAR新加坡干细胞协会之前，2002年至2007年Cole曼博士是新加坡人类胚胎干细胞公司、ES细胞国际的首席科学官和首席执行官。从20世纪80年代末到2002年，Cole曼博士是英国爱丁堡PPL治疗公司的研究主管，在那里他负责领导PPL的研究方案战略，也在PPL的融资回合发挥重要的作用，1996年在伦敦证券交易所上市。1996年这家公司引起了媒体的关注，因为它的体细胞核转移技术，诞生世界上第一个成体细胞—多利克隆羊。Cole曼博士曾在伯明翰华威的Oxford University有一个成功的大学生涯，在那里他是生物化学和伦敦的教授（如上所述）。上述公司或组织没有一个是母公司、子公司或本公司其他关联公司。Cole曼博士目前的兴趣是使用诱导多能干细胞发展人类疾病模型。
Alan Colman serves as a Director. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Colman served as a Director of Singapore Volition from April 1 2011 to December 15 2015 and currently serves as Chairman of the Scientific Advisory Board of Singapore Volition, a position he has held since April 5 2011. Dr. Colman received a BA -1971 MA -1975 and Ph.D. -1975 from Oxford University. Dr. Colman is currently a Visiting Scholar at the Harvard University Department of Stem Cell and Regenerative Biology. He also currently serves on the Scientific Advisory Board of Semma Therapeutics, Inc., a stem cell therapy company based in Cambridge, Massachusetts, a position he has held since December 2014. From 2007 to 2013 Dr. Colman served as the Executive Director of the Singapore Stem Cell Consortium. Concurrently, Dr. Colman was Professor of Regenerative Medicine at King’s College, London, U.K., from 2008 to 2009. Prior to joining the A*STAR Singapore Stem Cell Consortium, Dr. Colman was Chief Scientific Officer and then Chief Executive Officer for the Singaporean human embryonic stem cell company, ES Cell International from 2002 to 2007. Dr. Colman was the research director at PPL Therapeutics in Edinburgh, U.K., from the late 1980s until 2002 where he was responsible for leading PPL’s research program strategy, also playing a role in PPL’s financing rounds, culminating in its listing on the London Stock Exchange in 1996. PPL attracted considerable media attention because of its participation in the technique of somatic nuclear transfer that led to the world’s first sheep cloned from an adult cell, Dolly, in 1996. Dr. Colman had a successful university career in the Universities of Oxford, Warwick, Birmingham where he was Professor of Biochemistry and London (as mentioned above). None of the above companies or organizations is a parent, subsidiary or other affiliate of the Company. Dr. Colman’s current interest is the development of human disease models using induced pluripotent stem cells. - Alan Colman担任董事。在换股协议之前，2011年4月1日至2015年12月15日Cole曼博士曾担任新加坡 Volition的董事；自2011年4月5日起，担任新加坡 Volition科学顾问委员会主席。1971年，Cole曼博士获得Oxford University学士学位，1975年获得Oxford University硕士学位和Oxford University博士学位。Cole曼博士目前是Harvard University干细胞与再生生物学院的访问学者。2007年至2013年，Cole曼博士曾担任新加坡干细胞协会的执行主任。同时，2008年至2009年Cole曼博士是英国伦敦国王学院再生医学的教授。在加入A * STAR新加坡干细胞协会之前，2002年至2007年Cole曼博士是新加坡人类胚胎干细胞公司、ES细胞国际的首席科学官和首席执行官。从20世纪80年代末到2002年，Cole曼博士是英国爱丁堡PPL治疗公司的研究主管，在那里他负责领导PPL的研究方案战略，也在PPL的融资回合发挥重要的作用，1996年在伦敦证券交易所上市。1996年这家公司引起了媒体的关注，因为它的体细胞核转移技术，诞生世界上第一个成体细胞—多利克隆羊。Cole曼博士曾在伯明翰华威的Oxford University有一个成功的大学生涯，在那里他是生物化学和伦敦的教授（如上所述）。上述公司或组织没有一个是母公司、子公司或本公司其他关联公司。Cole曼博士目前的兴趣是使用诱导多能干细胞发展人类疾病模型。
- Alan Colman serves as a Director. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Colman served as a Director of Singapore Volition from April 1 2011 to December 15 2015 and currently serves as Chairman of the Scientific Advisory Board of Singapore Volition, a position he has held since April 5 2011. Dr. Colman received a BA -1971 MA -1975 and Ph.D. -1975 from Oxford University. Dr. Colman is currently a Visiting Scholar at the Harvard University Department of Stem Cell and Regenerative Biology. He also currently serves on the Scientific Advisory Board of Semma Therapeutics, Inc., a stem cell therapy company based in Cambridge, Massachusetts, a position he has held since December 2014. From 2007 to 2013 Dr. Colman served as the Executive Director of the Singapore Stem Cell Consortium. Concurrently, Dr. Colman was Professor of Regenerative Medicine at King’s College, London, U.K., from 2008 to 2009. Prior to joining the A*STAR Singapore Stem Cell Consortium, Dr. Colman was Chief Scientific Officer and then Chief Executive Officer for the Singaporean human embryonic stem cell company, ES Cell International from 2002 to 2007. Dr. Colman was the research director at PPL Therapeutics in Edinburgh, U.K., from the late 1980s until 2002 where he was responsible for leading PPL’s research program strategy, also playing a role in PPL’s financing rounds, culminating in its listing on the London Stock Exchange in 1996. PPL attracted considerable media attention because of its participation in the technique of somatic nuclear transfer that led to the world’s first sheep cloned from an adult cell, Dolly, in 1996. Dr. Colman had a successful university career in the Universities of Oxford, Warwick, Birmingham where he was Professor of Biochemistry and London (as mentioned above). None of the above companies or organizations is a parent, subsidiary or other affiliate of the Company. Dr. Colman’s current interest is the development of human disease models using induced pluripotent stem cells.
- Habib Skaff
-
Habib Skaff 担任董事。在换股协议之前，2011年4月4日至2014年5月31日Skaff 博士曾担任新加坡Volition的科学顾问委员会成员。2004年，Skaff博士共同创办Intezyne Technologies，并担任该公司的首席执行官，那里负责今后战略规划的制定和实施。Skaff 博士和首席科学官紧密合作，制定和实施Intezyne的知识产权战略，以及与潜在合作伙伴建立联盟。他还通过债务和股权融资领导Intezyne的筹款，并在这方面与首席财务官密切合作。他也是Intezyne的董事会主席和董事长。Skaff 博士目前担任Skaff Corporation of America的董事长，自1999年以来他一直担任此职务。他指导战略规划，但不参与日常的运作。此外，自2001年以来Skaff博士共同撰写11个同行评审的科学论文，并是正在申请的34项共同发明者，在化学、纳米技术和生物技术领域。Skaff 博士是一名合成化学家，专攻纳米技术的领域；他的博士研究集中在有机和聚合配体的设计，半导体纳米粒子的封装和修饰在物理、光学、电子和纳米粒子装配性能。
Habib Skaff serves as a Director. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Skaff served as a Scientific Advisory Board Member of Singapore Volition between April 4 2011 and May 31 2014. Dr. Skaff currently serves as Managing Partner of Cedar Capital Holdings, LLC, where he heads operations as well as acquisitions of companies in fields varying from wound care to recycling. Dr. Skaff co-founded Intezyne Technologies in 2004 and served as its Chief Executive Officer until 2016. At Intezyne, Dr. Skaff was responsible for establishing and implementing strategic planning for the future, working closely with the Chief Scientific Officer to develop and implement Intezyne's intellectual property strategy as well as establishing alliances with potential partners. As Chief Executive Officer, Dr. Skaff led Intezyne's fundraising through debt and equity financing and worked closely with the Chief Financial Officer in this capacity. In addition, since 2001 Dr. Skaff has co-authored 11 peer-reviewed scientific papers and is a co-inventor on 34 pending or issued patents in the fields of chemistry, nanotechnology and biotechnology. Dr. Skaff works as a synthetic chemist specializing in the area of nanotechnology; his doctoral studies focused on the design of organic and polymeric ligands for the encapsulation of semiconductor nanoparticles and modification of the physical, optical, electronic, and assembly properties of the nanoparticles. Due to his extensive scholarly work and inventions in the fields of chemistry and biotechnology, the Board of Directors feels that Dr. Skaff is a valuable asset to the Company. - Habib Skaff 担任董事。在换股协议之前，2011年4月4日至2014年5月31日Skaff 博士曾担任新加坡Volition的科学顾问委员会成员。2004年，Skaff博士共同创办Intezyne Technologies，并担任该公司的首席执行官，那里负责今后战略规划的制定和实施。Skaff 博士和首席科学官紧密合作，制定和实施Intezyne的知识产权战略，以及与潜在合作伙伴建立联盟。他还通过债务和股权融资领导Intezyne的筹款，并在这方面与首席财务官密切合作。他也是Intezyne的董事会主席和董事长。Skaff 博士目前担任Skaff Corporation of America的董事长，自1999年以来他一直担任此职务。他指导战略规划，但不参与日常的运作。此外，自2001年以来Skaff博士共同撰写11个同行评审的科学论文，并是正在申请的34项共同发明者，在化学、纳米技术和生物技术领域。Skaff 博士是一名合成化学家，专攻纳米技术的领域；他的博士研究集中在有机和聚合配体的设计，半导体纳米粒子的封装和修饰在物理、光学、电子和纳米粒子装配性能。
- Habib Skaff serves as a Director. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Skaff served as a Scientific Advisory Board Member of Singapore Volition between April 4 2011 and May 31 2014. Dr. Skaff currently serves as Managing Partner of Cedar Capital Holdings, LLC, where he heads operations as well as acquisitions of companies in fields varying from wound care to recycling. Dr. Skaff co-founded Intezyne Technologies in 2004 and served as its Chief Executive Officer until 2016. At Intezyne, Dr. Skaff was responsible for establishing and implementing strategic planning for the future, working closely with the Chief Scientific Officer to develop and implement Intezyne's intellectual property strategy as well as establishing alliances with potential partners. As Chief Executive Officer, Dr. Skaff led Intezyne's fundraising through debt and equity financing and worked closely with the Chief Financial Officer in this capacity. In addition, since 2001 Dr. Skaff has co-authored 11 peer-reviewed scientific papers and is a co-inventor on 34 pending or issued patents in the fields of chemistry, nanotechnology and biotechnology. Dr. Skaff works as a synthetic chemist specializing in the area of nanotechnology; his doctoral studies focused on the design of organic and polymeric ligands for the encapsulation of semiconductor nanoparticles and modification of the physical, optical, electronic, and assembly properties of the nanoparticles. Due to his extensive scholarly work and inventions in the fields of chemistry and biotechnology, the Board of Directors feels that Dr. Skaff is a valuable asset to the Company.
- Edward Futcher
-
Edward Futcher担任董事。Futch博士拥有 University of London的物理学士学位和物理学博士学位。他于2003年共同创办了Azima, Inc.（提供先进的机器诊断的一家公司），2003年至2008年担任工程副总裁，负责工程，信息技术和客户支持团队。在此之前，从1997年到2003年，Futcher博士担任interWAVE Communications International, Ltd.（一家提供GSM和CDMA蜂窝基础设施设备的公司）的副总裁，在那里他负责全球研发组织的收购和临时管理的运营管理。1997年至1999年，Futchr博士还担任interWAVE Communications的工程副总裁 。1994年至1997年，Futer博士担任Tellabs, Inc.（一家电信设备供应商）的工程总监。
Edward Futcher serves as a Director. Since 1997 Dr. Futcher has held non-executive directorships with a variety of private companies. He co-founded Azima, Inc. in 2003 a company that provides advanced machine diagnosis to large industrial facilities and, from 2003 to 2008 served as its Vice President of Engineering with responsibility for the engineering, information technology and customer support groups. Prior to that, from 1997 to 2003 Dr. Futcher served as Vice President of Technology of interWAVE Communications International, Ltd., a company providing GSM and CDMA cellular infrastructure equipment, where he was responsible for operational management of acquisitions and interim management of the worldwide research and development organization. From 1997 to 1999 Dr. Futcher also served as Vice President of Engineering of interWAVE Communications. From 1994 to 1997 Dr. Futcher was Director of Engineering at Tellabs, Inc., a telecommunications equipment supplier. - Edward Futcher担任董事。Futch博士拥有 University of London的物理学士学位和物理学博士学位。他于2003年共同创办了Azima, Inc.（提供先进的机器诊断的一家公司），2003年至2008年担任工程副总裁，负责工程，信息技术和客户支持团队。在此之前，从1997年到2003年，Futcher博士担任interWAVE Communications International, Ltd.（一家提供GSM和CDMA蜂窝基础设施设备的公司）的副总裁，在那里他负责全球研发组织的收购和临时管理的运营管理。1997年至1999年，Futchr博士还担任interWAVE Communications的工程副总裁 。1994年至1997年，Futer博士担任Tellabs, Inc.（一家电信设备供应商）的工程总监。
- Edward Futcher serves as a Director. Since 1997 Dr. Futcher has held non-executive directorships with a variety of private companies. He co-founded Azima, Inc. in 2003 a company that provides advanced machine diagnosis to large industrial facilities and, from 2003 to 2008 served as its Vice President of Engineering with responsibility for the engineering, information technology and customer support groups. Prior to that, from 1997 to 2003 Dr. Futcher served as Vice President of Technology of interWAVE Communications International, Ltd., a company providing GSM and CDMA cellular infrastructure equipment, where he was responsible for operational management of acquisitions and interim management of the worldwide research and development organization. From 1997 to 1999 Dr. Futcher also served as Vice President of Engineering of interWAVE Communications. From 1994 to 1997 Dr. Futcher was Director of Engineering at Tellabs, Inc., a telecommunications equipment supplier.
高管简历
中英对照 | 中文 | 英文- Cameron Reynolds
Cameron Reynolds 担任我们总裁，首席执行官和董事。在换股协议之前，他是新加坡Volition的首席执行官和董事，自2010年8月5日起一直担任此职务。自2010年10月27日起，他也担任比利时 Volition的董事；2012年1月18日至2015年7月24日，担任董事总经理；自2011年3月7日起，担任Hypergenomics的董事兼首席执行官；2015年11月13日，被任命为Volition Diagnostics UK Limited的董事兼首席执行官。2004年至2011年，Reynolds先生创办并担任Mining House Limited的管理董事，他在那里负责识别潜在的矿业项目、协调初步评估和保护AIM、TSX和美国场外交易的公司融资。2002年至2003年，Reynolds先生进一步教育，获得工商管理硕士学位。1998年至2001年，Reynolds先生曾担任 Probio, Inc.（一家动物生物技术领域知识产权的商业化公司，包括University of Hawaii的转基因和克隆研究）的商业总监。 Reynolds先生的主要职责是管理University of Hawaii所有法律和合同问题；实施专利战略；管理所有股东问题，包括并购的法律和合同文件；总行管理；预算控制；团队建设和招聘。此外，1996年Reynolds先生曾在Integrated Coffee Technologies担任初级管理职位，这是一家转基因咖啡公司在那里他负责业务计划的制定、办公管理、招聘和企业发展。1994年开始Reynolds先生在Southern China Group任职，在那里担任地区经理，在香港和云南设立业务。2005年至目前，Reynolds先生多次担任董事会董事职务，包括Atlantic Mining PLC； Carbon Mining PLC, Magellan Copper 和 Gold Carbon Mining和MCG都成为Solfotara Mining and Copper Development Corp.的一部分； KAL Energy Inc.（KALG，OTC），Iofina Natural Gas PLC（IOF，AIM）；Canyon Copper Corp.（TSX.V：CNC，OTCBB：CNYC）和Hunter Bay Resources（HBY，TSX-V）。
Cameron Reynolds serves as our President, Chief Executive Officer and Director. Prior to completion of the transactions under the Share Exchange Agreement, he was Chief Executive Officer and Director of Singapore Volition, a position he held since August 5 2010. He is also a Director of Belgian Volition since October 27 2010 serving as Managing Director between January 18 2012 and July 24 2015 a Director and Chief Executive Officer of Hypergenomics since March 7 2011 was appointed Director and Chief Executive Officer of Volition Diagnostics on November 13 2015 and was appointed Director of Volition America on February 3 2017. Since February 2017 Mr. Reynolds has also served as a non-executive director of Ucroo Inc., a developer of a secure web and mobile platform that integrates with existing college systems to provide a thriving digital campus where students are better connected, supported and engaged, and, since July 2018 as a non-executive director of OBJ Limited ASX: OBJ, a developer of magnetic, micro-array drug and ingredient delivery technologies for use in pharmaceutical, cosmetic and skincare, and consumer healthcare industries. From 2004 until 2011 Mr. Reynolds founded and served as Managing Director and Director of Mining House, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on the AIM, the TSX and the U.S. OTC. Mr. Reynolds furthered his education between 2002 and 2003 as he undertook an MBA. From 1998 until 2001 Mr. Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds’ main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all stockholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment. Furthermore, Mr. Reynolds held a junior management position in 1996 at Integrated Coffee Technologies, a genetically modified coffee company where he was responsible for business plan creation, office management, recruitment, and business development. Starting in 1994 Mr. Reynolds was working for Southern China Group, where as regional manager he set up operations in Hong Kong and Yunnan. Between 2005 and 2011 Mr. Reynolds held a number of board directorships including Atlantic Mining PLC; Carbon Mining PLC; Magellan Copper and Gold (Carbon Mining and MCG both became part of Solfotara Mining and Copper Development Corp.); KAL Energy Inc. (OTC: KALG); Iofina Natural Gas PLC (AIM: IOF); Canyon Copper Corp. (TSX-V: CNC, OTCBB: CNYC); and Hunter Bay Resources (TSX-V: HBY).- Cameron Reynolds 担任我们总裁，首席执行官和董事。在换股协议之前，他是新加坡Volition的首席执行官和董事，自2010年8月5日起一直担任此职务。自2010年10月27日起，他也担任比利时 Volition的董事；2012年1月18日至2015年7月24日，担任董事总经理；自2011年3月7日起，担任Hypergenomics的董事兼首席执行官；2015年11月13日，被任命为Volition Diagnostics UK Limited的董事兼首席执行官。2004年至2011年，Reynolds先生创办并担任Mining House Limited的管理董事，他在那里负责识别潜在的矿业项目、协调初步评估和保护AIM、TSX和美国场外交易的公司融资。2002年至2003年，Reynolds先生进一步教育，获得工商管理硕士学位。1998年至2001年，Reynolds先生曾担任 Probio, Inc.（一家动物生物技术领域知识产权的商业化公司，包括University of Hawaii的转基因和克隆研究）的商业总监。 Reynolds先生的主要职责是管理University of Hawaii所有法律和合同问题；实施专利战略；管理所有股东问题，包括并购的法律和合同文件；总行管理；预算控制；团队建设和招聘。此外，1996年Reynolds先生曾在Integrated Coffee Technologies担任初级管理职位，这是一家转基因咖啡公司在那里他负责业务计划的制定、办公管理、招聘和企业发展。1994年开始Reynolds先生在Southern China Group任职，在那里担任地区经理，在香港和云南设立业务。2005年至目前，Reynolds先生多次担任董事会董事职务，包括Atlantic Mining PLC； Carbon Mining PLC, Magellan Copper 和 Gold Carbon Mining和MCG都成为Solfotara Mining and Copper Development Corp.的一部分； KAL Energy Inc.（KALG，OTC），Iofina Natural Gas PLC（IOF，AIM）；Canyon Copper Corp.（TSX.V：CNC，OTCBB：CNYC）和Hunter Bay Resources（HBY，TSX-V）。
- Cameron Reynolds serves as our President, Chief Executive Officer and Director. Prior to completion of the transactions under the Share Exchange Agreement, he was Chief Executive Officer and Director of Singapore Volition, a position he held since August 5 2010. He is also a Director of Belgian Volition since October 27 2010 serving as Managing Director between January 18 2012 and July 24 2015 a Director and Chief Executive Officer of Hypergenomics since March 7 2011 was appointed Director and Chief Executive Officer of Volition Diagnostics on November 13 2015 and was appointed Director of Volition America on February 3 2017. Since February 2017 Mr. Reynolds has also served as a non-executive director of Ucroo Inc., a developer of a secure web and mobile platform that integrates with existing college systems to provide a thriving digital campus where students are better connected, supported and engaged, and, since July 2018 as a non-executive director of OBJ Limited ASX: OBJ, a developer of magnetic, micro-array drug and ingredient delivery technologies for use in pharmaceutical, cosmetic and skincare, and consumer healthcare industries. From 2004 until 2011 Mr. Reynolds founded and served as Managing Director and Director of Mining House, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on the AIM, the TSX and the U.S. OTC. Mr. Reynolds furthered his education between 2002 and 2003 as he undertook an MBA. From 1998 until 2001 Mr. Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds’ main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all stockholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment. Furthermore, Mr. Reynolds held a junior management position in 1996 at Integrated Coffee Technologies, a genetically modified coffee company where he was responsible for business plan creation, office management, recruitment, and business development. Starting in 1994 Mr. Reynolds was working for Southern China Group, where as regional manager he set up operations in Hong Kong and Yunnan. Between 2005 and 2011 Mr. Reynolds held a number of board directorships including Atlantic Mining PLC; Carbon Mining PLC; Magellan Copper and Gold (Carbon Mining and MCG both became part of Solfotara Mining and Copper Development Corp.); KAL Energy Inc. (OTC: KALG); Iofina Natural Gas PLC (AIM: IOF); Canyon Copper Corp. (TSX-V: CNC, OTCBB: CNYC); and Hunter Bay Resources (TSX-V: HBY).
- Rodney Rootsaert
Rodney Rootsaert，本公司秘书。在2011年9月26日本公司，后来以股东Standard Capital Corporation的名义，与Singapore Volition及其股东的换股协议签署完成之前，他从2010年8月6日起，担任Singapore Volition的行政与法律官。2007年至今，他一直担任Mining House Ltd.的董事、秘书，他的职责是确保公司的业务活动符合法定、监管方面的所有要求。2007-2011，他曾担任Magellan Copper and Gold Plc的秘书，他的职责是维护并准备公司文件、客户、合同。
Rodney Rootsaert serves as our Corporate Secretary. Prior to the completion of the transactions under the Share Exchange Agreement, he was the Administration and Legal Officer of Singapore Volition, a position he held since August 6 2010. Mr. Rootsaert became a Director of Singapore Volition and Hypergenomics on December 15 2015. He has been a Director and Secretary of Belgian Volition since October 4 2010 and was appointed Director of Volition Diagnostics on November 13 2015. Mr. Rootsaert concurrently serves as director and corporate secretary of Mining House Ltd., positions he has had since 2007. His responsibilities include ensuring compliance with all relevant statutory and regulatory requirements. From 2007 until 2011 Mr. Rootsaert served as corporate secretary for Magellan Copper and Gold Plc., where his duties included maintaining and preparing company documents, accounts and contracts.- Rodney Rootsaert，本公司秘书。在2011年9月26日本公司，后来以股东Standard Capital Corporation的名义，与Singapore Volition及其股东的换股协议签署完成之前，他从2010年8月6日起，担任Singapore Volition的行政与法律官。2007年至今，他一直担任Mining House Ltd.的董事、秘书，他的职责是确保公司的业务活动符合法定、监管方面的所有要求。2007-2011，他曾担任Magellan Copper and Gold Plc的秘书，他的职责是维护并准备公司文件、客户、合同。
- Rodney Rootsaert serves as our Corporate Secretary. Prior to the completion of the transactions under the Share Exchange Agreement, he was the Administration and Legal Officer of Singapore Volition, a position he held since August 6 2010. Mr. Rootsaert became a Director of Singapore Volition and Hypergenomics on December 15 2015. He has been a Director and Secretary of Belgian Volition since October 4 2010 and was appointed Director of Volition Diagnostics on November 13 2015. Mr. Rootsaert concurrently serves as director and corporate secretary of Mining House Ltd., positions he has had since 2007. His responsibilities include ensuring compliance with all relevant statutory and regulatory requirements. From 2007 until 2011 Mr. Rootsaert served as corporate secretary for Magellan Copper and Gold Plc., where his duties included maintaining and preparing company documents, accounts and contracts.
- Jason Terrell
Jason Terrell，他担任美国业务的首席医疗官和负责人。他被任命为首席医疗官和全职美国业务负责人并于2016年1月1日生效。此前2013年3月以来，他曾担任公司兼职的首席医疗官和美国业务负责人。他在2013年1月和2015年10月之间，他担任CDEX Inc.（上市公司，发展中药物验证技术）董事会职务。在2012年1月和2015年10月之间，他担任CDEX Inc医疗董事。此外在过去的六年里，他已经建造和出售多个私人诊断实验室。他目前担任Any Lab Test Now的国家特许经营企业医疗董事，给他监督14个州的70多家特许经营店。他是University of Texas和MD Anderson Cancer Center附属机构的德克萨斯州医生，拥有临床医学和实验室诊断业务的经验。
Jason Terrell serves as our Chief Medical Officer and Head of U.S. Operations. Effective January 1 2016 Dr. Terrell was appointed to the position of Chief Medical Officer and Head of U.S. Operations on a full-time basis, having previously served in a part-time capacity as the Company’s Chief Medical Officer and Head of U.S. Operations since March 2013. On February 3 2017 Dr. Terrell was appointed Director of Volition America, Inc. Since February 2017 Dr. Terrell has also concurrently served as both a director and Chief Medical Diagnostics Officer of Generex Biotechnology Corporation OTCMKTS : GNBT, a publicly-held biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, and additionally as the non-executive chairman of the board of directors of Kiromic BioPharma, Inc. (a private company). Between January 2013 and October 2015 Dr. Terrell served on the board of directors of CDEX Inc., a publicly-held company developing drug validation technology, and between January 2012 and October 2015 as Medical Director of CDEX Inc. In addition, over the last six years, Dr. Terrell has built and sold multiple private diagnostic laboratories and currently serves as a National Franchise Corporate Medical Director for Any Lab Test Now, giving him oversight of over 70 franchises in 14 states. Dr. Terrell is a Texas-based doctor educated at the University of Texas and its affiliate MD Anderson Cancer Center, with expertise in both clinical medicine and the laboratory diagnostics business.- Jason Terrell，他担任美国业务的首席医疗官和负责人。他被任命为首席医疗官和全职美国业务负责人并于2016年1月1日生效。此前2013年3月以来，他曾担任公司兼职的首席医疗官和美国业务负责人。他在2013年1月和2015年10月之间，他担任CDEX Inc.（上市公司，发展中药物验证技术）董事会职务。在2012年1月和2015年10月之间，他担任CDEX Inc医疗董事。此外在过去的六年里，他已经建造和出售多个私人诊断实验室。他目前担任Any Lab Test Now的国家特许经营企业医疗董事，给他监督14个州的70多家特许经营店。他是University of Texas和MD Anderson Cancer Center附属机构的德克萨斯州医生，拥有临床医学和实验室诊断业务的经验。
- Jason Terrell serves as our Chief Medical Officer and Head of U.S. Operations. Effective January 1 2016 Dr. Terrell was appointed to the position of Chief Medical Officer and Head of U.S. Operations on a full-time basis, having previously served in a part-time capacity as the Company’s Chief Medical Officer and Head of U.S. Operations since March 2013. On February 3 2017 Dr. Terrell was appointed Director of Volition America, Inc. Since February 2017 Dr. Terrell has also concurrently served as both a director and Chief Medical Diagnostics Officer of Generex Biotechnology Corporation OTCMKTS : GNBT, a publicly-held biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, and additionally as the non-executive chairman of the board of directors of Kiromic BioPharma, Inc. (a private company). Between January 2013 and October 2015 Dr. Terrell served on the board of directors of CDEX Inc., a publicly-held company developing drug validation technology, and between January 2012 and October 2015 as Medical Director of CDEX Inc. In addition, over the last six years, Dr. Terrell has built and sold multiple private diagnostic laboratories and currently serves as a National Franchise Corporate Medical Director for Any Lab Test Now, giving him oversight of over 70 franchises in 14 states. Dr. Terrell is a Texas-based doctor educated at the University of Texas and its affiliate MD Anderson Cancer Center, with expertise in both clinical medicine and the laboratory diagnostics business.
- Martin Faulkes
Martin Faulkes担任董事会执行主席。在换股协议之前，2010年8月18日至2015年12月15日Faulkes博士曾担任新加坡Volition的董事；2011年3月22日至2015年12月15日，担任新加坡Volition的董事会执行主席。自2011年8月10日起，Faulkes先生一直担任比利时Volition的董事。1998年至今，Faulkes博士一直专注于慈善活动，如担任Dill Faulkes Educational Trust（一家英国注册的慈善机构）的创办人及捐助人，在那里他是主席。他还任职英国剑桥800周年活动的委员会。在Faulkes博士的慈善活动前，他创立Triad公共有限公司（一家计算机软件开发公司，提供系统和商界顾问），在那里他是1987年至1998年担任董事，并负责公司的财务控制。1985年至1987年，他成为了System Programming Ltd.（向航空公司、公用事业公司、银行和Insurance Company提供计算机编程服务的一家公司）的执行董事，在那里他负责该业务的所有方面的业务。在 System Programming Ltd.之前，1979年至1984年Faulkes博士担任Logica Inc.（一家向所有行业提供定制软件的公司，但主要是银行和通信公司）的总裁兼首席执行官。 Faulkes博士负责业务的各个方面；即销售、财务、招聘、员工管理和项目控制。
Martin Faulkes serves as Executive Chairman of the Board of Directors. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Faulkes served as a Director of Singapore Volition from August 18 2010 to December 15 2015 and as Executive Chairman of the Board of Directors of Singapore Volition from March 22 2011 until December 15 2015. Dr. Faulkes also served as a Director of Belgian Volition between August 10 2011 and March 31 2016. From 1998 until the present day, Dr. Faulkes has focused on charitable activities, as the founder and sole benefactor of The Dill Faulkes Educational Trust, a U.K. registered charity, where he is Chairman. He also sits on the board of the Cambridge 800th Anniversary Campaign in the U.K. Prior to Dr. Faulkes’s charitable activities he founded Triad Plc., a computer software development company that provides systems and consultants to the business community, where he was a Director from 1987 to 1998 and responsible for controlling the company financially. From 1985 to 1987 he became Managing Director of System Programming Ltd., a company that provides computer programming for systems in businesses such as airlines, utility companies, banks, and insurance companies, where he was responsible for all aspects of the business. Prior to System Programming Ltd., Dr. Faulkes served from 1979 to 1984 as founder, President and Chief Executive Officer for Logica Inc., a company providing bespoke software to all industries but mainly banks and communications companies. Dr. Faulkes was responsible for all aspects of the business, including sales, finance, recruitment, staff management and project control.- Martin Faulkes担任董事会执行主席。在换股协议之前，2010年8月18日至2015年12月15日Faulkes博士曾担任新加坡Volition的董事；2011年3月22日至2015年12月15日，担任新加坡Volition的董事会执行主席。自2011年8月10日起，Faulkes先生一直担任比利时Volition的董事。1998年至今，Faulkes博士一直专注于慈善活动，如担任Dill Faulkes Educational Trust（一家英国注册的慈善机构）的创办人及捐助人，在那里他是主席。他还任职英国剑桥800周年活动的委员会。在Faulkes博士的慈善活动前，他创立Triad公共有限公司（一家计算机软件开发公司，提供系统和商界顾问），在那里他是1987年至1998年担任董事，并负责公司的财务控制。1985年至1987年，他成为了System Programming Ltd.（向航空公司、公用事业公司、银行和Insurance Company提供计算机编程服务的一家公司）的执行董事，在那里他负责该业务的所有方面的业务。在 System Programming Ltd.之前，1979年至1984年Faulkes博士担任Logica Inc.（一家向所有行业提供定制软件的公司，但主要是银行和通信公司）的总裁兼首席执行官。 Faulkes博士负责业务的各个方面；即销售、财务、招聘、员工管理和项目控制。
- Martin Faulkes serves as Executive Chairman of the Board of Directors. Prior to completion of the transactions under the Share Exchange Agreement, Dr. Faulkes served as a Director of Singapore Volition from August 18 2010 to December 15 2015 and as Executive Chairman of the Board of Directors of Singapore Volition from March 22 2011 until December 15 2015. Dr. Faulkes also served as a Director of Belgian Volition between August 10 2011 and March 31 2016. From 1998 until the present day, Dr. Faulkes has focused on charitable activities, as the founder and sole benefactor of The Dill Faulkes Educational Trust, a U.K. registered charity, where he is Chairman. He also sits on the board of the Cambridge 800th Anniversary Campaign in the U.K. Prior to Dr. Faulkes’s charitable activities he founded Triad Plc., a computer software development company that provides systems and consultants to the business community, where he was a Director from 1987 to 1998 and responsible for controlling the company financially. From 1985 to 1987 he became Managing Director of System Programming Ltd., a company that provides computer programming for systems in businesses such as airlines, utility companies, banks, and insurance companies, where he was responsible for all aspects of the business. Prior to System Programming Ltd., Dr. Faulkes served from 1979 to 1984 as founder, President and Chief Executive Officer for Logica Inc., a company providing bespoke software to all industries but mainly banks and communications companies. Dr. Faulkes was responsible for all aspects of the business, including sales, finance, recruitment, staff management and project control.
- Jacob Micallef
Jacob Micallef，担任公司的首席科学官，也作为首席科学官。他也曾担任Belgian Volition的董事（2011年8月10日至2016年3月31日）。达成共享交换协议之前，他曾担任Belgian Volition的高级执行官（2010年10月11日以来），但不参与Singapore Volition。他于2004年加入Cronos Therapeutics Limited（Cronos，并于2006年在英国上市，成为Valirx plc）。他继续担任Valirx plc的技术官，在那里他注册the HyperGenomics 、Nucleosomics 技术，并共同创立ValiBio SA（现称为Belgian Volition）。2004年至2007年，他曾向CASS Business School的4个学校的科学研究人员教授科学和企业课程（加入Cronos公司之前）。他于2001年共同创立Gene Expression Technologies，并于1999年获得他自己的工商管理硕士学位，在那里他曾成功领导GeneICE技术的化学开发，以及实现GeneICE分子制造。他也曾领导GeneICE公司与Bayer AG的合同业务开发和采购。15年期间，他于1985年开始任职the World Health Organization（WHO）。任职the WHO期间，他曾开发生殖健康和癌症领域的新诊断产品。他于1990年开始开发WHO的一种新的诊断技术平台（于1992年推出），并支持13测试。他还发起和实施内部生产，此前外包给Abbott Diagnostics Inc.，以及WHO的这些产品的全球分销。他于1990年创立Immunometrics Ltd.（一个非营利WHO公司，世界各地销售和分销这些诊断产品）。
Jacob Micallef serves as the Company’s Chief Scientific Officer. Dr. Micallef also served as a Director of Belgian Volition between August 10 2011 and March 31 2016. Prior to the Share Exchange Agreement, he served as a Science Executive Officer of Belgian Volition since October 11 2010 but was not otherwise involved with Singapore Volition. Dr. Micallef joined Cronos Therapeutics Limited, or Cronos, in 2004 and, in 2006 Cronos was listed in the U.K. on the AIM, becoming Valirx plc, or Valirx. Dr. Micallef continued to work as Technical Officer for Valirx, where he in-licensed the Hypergenomics® and Nucleosomics® technologies and co-founded ValiBio SA, which is now Belgian Volition. From 2004 to 2007 he taught “science and enterprise” to science research workers from four universities at CASS Business School before joining Cronos. In 2001 Dr. Micallef co-founded Gene Expression Technologies, after getting his MBA in 1999 where he successfully led the development of the chemistry of the GeneICE technology and implemented the manufacture of GeneICE molecules. He also played a major role in business development and procured a GeneICE contract with Bayer AG. Over a 15-year period, starting in 1985 Dr. Micallef worked for the World Health Organization, or WHO. While working for the WHO, Dr. Micallef developed new diagnostic products in the areas of reproductive health and cancer. In 1990 he commenced development of a new diagnostic technology platform for WHO which was launched in 1992 and supported 13 tests. Dr. Micallef also initiated and implemented in-house manufacture previously outsourced to Abbott Diagnostics Inc. and world-wide distribution of these products for WHO. Also in 1990 he started a “not-for-profit” WHO company, Immunometrics Ltd., which marketed and distributed those diagnostic products worldwide.- Jacob Micallef，担任公司的首席科学官，也作为首席科学官。他也曾担任Belgian Volition的董事（2011年8月10日至2016年3月31日）。达成共享交换协议之前，他曾担任Belgian Volition的高级执行官（2010年10月11日以来），但不参与Singapore Volition。他于2004年加入Cronos Therapeutics Limited（Cronos，并于2006年在英国上市，成为Valirx plc）。他继续担任Valirx plc的技术官，在那里他注册the HyperGenomics 、Nucleosomics 技术，并共同创立ValiBio SA（现称为Belgian Volition）。2004年至2007年，他曾向CASS Business School的4个学校的科学研究人员教授科学和企业课程（加入Cronos公司之前）。他于2001年共同创立Gene Expression Technologies，并于1999年获得他自己的工商管理硕士学位，在那里他曾成功领导GeneICE技术的化学开发，以及实现GeneICE分子制造。他也曾领导GeneICE公司与Bayer AG的合同业务开发和采购。15年期间，他于1985年开始任职the World Health Organization（WHO）。任职the WHO期间，他曾开发生殖健康和癌症领域的新诊断产品。他于1990年开始开发WHO的一种新的诊断技术平台（于1992年推出），并支持13测试。他还发起和实施内部生产，此前外包给Abbott Diagnostics Inc.，以及WHO的这些产品的全球分销。他于1990年创立Immunometrics Ltd.（一个非营利WHO公司，世界各地销售和分销这些诊断产品）。
- Jacob Micallef serves as the Company’s Chief Scientific Officer. Dr. Micallef also served as a Director of Belgian Volition between August 10 2011 and March 31 2016. Prior to the Share Exchange Agreement, he served as a Science Executive Officer of Belgian Volition since October 11 2010 but was not otherwise involved with Singapore Volition. Dr. Micallef joined Cronos Therapeutics Limited, or Cronos, in 2004 and, in 2006 Cronos was listed in the U.K. on the AIM, becoming Valirx plc, or Valirx. Dr. Micallef continued to work as Technical Officer for Valirx, where he in-licensed the Hypergenomics® and Nucleosomics® technologies and co-founded ValiBio SA, which is now Belgian Volition. From 2004 to 2007 he taught “science and enterprise” to science research workers from four universities at CASS Business School before joining Cronos. In 2001 Dr. Micallef co-founded Gene Expression Technologies, after getting his MBA in 1999 where he successfully led the development of the chemistry of the GeneICE technology and implemented the manufacture of GeneICE molecules. He also played a major role in business development and procured a GeneICE contract with Bayer AG. Over a 15-year period, starting in 1985 Dr. Micallef worked for the World Health Organization, or WHO. While working for the WHO, Dr. Micallef developed new diagnostic products in the areas of reproductive health and cancer. In 1990 he commenced development of a new diagnostic technology platform for WHO which was launched in 1992 and supported 13 tests. Dr. Micallef also initiated and implemented in-house manufacture previously outsourced to Abbott Diagnostics Inc. and world-wide distribution of these products for WHO. Also in 1990 he started a “not-for-profit” WHO company, Immunometrics Ltd., which marketed and distributed those diagnostic products worldwide.
- David Vanston
David Vanston自2017年4月起担任我们的首席财务官兼财务主管。Vanston先生此前曾于2016年至2017年受聘于Octo Telematics（一家位于波士顿的高增长技术公司），在那里他曾担任美国业务高级总监。在加入Octo Telematics之前，他曾于2015年至2016年担任明尼阿波利斯早期医疗公司Excorp Medical，Inc.的Vice President，2011年至2015年，他曾担任多家上市/私营公司的财务副总裁兼首席财务官，包括2013年担任Growhow Ltd.的首席财务官，负责管理和监督会计、财务、税务、财政、财务规划和分析。Vanston先生是一名注册会计师，持有Warwick Business School工商管理硕士学位。
David Vanston serves as our Chief Financial Officer and Treasurer, a position he has held since April 2017. Mr. Vanston was previously employed at Octo Telematics from 2016 to 2017 a high-growth technology company based in Boston, where he was the Senior Controller for the United States business. Prior to joining Octo Telematics, he was Vice President of Excorp Medical, Inc., an early-stage medical company in Minneapolis, from 2015 until 2016 and, from 2011 to 2015 he served as VP Finance/CFO in a consultant capacity to various listed/private companies including serving as Chief Financial Officer for GrowHow Ltd in 2013 in which Mr. Vanston managed and oversaw accounting, finance, tax, treasury, financial planning and analysis. Mr. Vanston is a certified chartered accountant and holds an MBA from Warwick Business School.- David Vanston自2017年4月起担任我们的首席财务官兼财务主管。Vanston先生此前曾于2016年至2017年受聘于Octo Telematics（一家位于波士顿的高增长技术公司），在那里他曾担任美国业务高级总监。在加入Octo Telematics之前，他曾于2015年至2016年担任明尼阿波利斯早期医疗公司Excorp Medical，Inc.的Vice President，2011年至2015年，他曾担任多家上市/私营公司的财务副总裁兼首席财务官，包括2013年担任Growhow Ltd.的首席财务官，负责管理和监督会计、财务、税务、财政、财务规划和分析。Vanston先生是一名注册会计师，持有Warwick Business School工商管理硕士学位。
- David Vanston serves as our Chief Financial Officer and Treasurer, a position he has held since April 2017. Mr. Vanston was previously employed at Octo Telematics from 2016 to 2017 a high-growth technology company based in Boston, where he was the Senior Controller for the United States business. Prior to joining Octo Telematics, he was Vice President of Excorp Medical, Inc., an early-stage medical company in Minneapolis, from 2015 until 2016 and, from 2011 to 2015 he served as VP Finance/CFO in a consultant capacity to various listed/private companies including serving as Chief Financial Officer for GrowHow Ltd in 2013 in which Mr. Vanston managed and oversaw accounting, finance, tax, treasury, financial planning and analysis. Mr. Vanston is a certified chartered accountant and holds an MBA from Warwick Business School.